174 related articles for article (PubMed ID: 24935174)
41. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
42. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
43. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.
Kim EY; Kim A; Kim SK; Chang YS
Cancer Lett; 2015 Mar; 358(1):85-91. PubMed ID: 25541062
[TBL] [Abstract][Full Text] [Related]
44. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
45. Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer.
Yasumoto M; Sakamoto E; Ogasawara S; Isobe T; Kizaki J; Sumi A; Kusano H; Akiba J; Torimura T; Akagi Y; Itadani H; Kobayashi T; Hasako S; Kumazaki M; Mizuarai S; Oie S; Yano H
Cancer Med; 2017 Jan; 6(1):235-244. PubMed ID: 27891760
[TBL] [Abstract][Full Text] [Related]
46. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
47. In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
Kuboki Y; Schatz CA; Koechert K; Schubert S; Feng J; Wittemer-Rump S; Ziegelbauer K; Krahn T; Nagatsuma AK; Ochiai A
Gastric Cancer; 2018 May; 21(3):401-412. PubMed ID: 28852882
[TBL] [Abstract][Full Text] [Related]
48. Identification of druggable cancer driver genes amplified across TCGA datasets.
Chen Y; McGee J; Chen X; Doman TN; Gong X; Zhang Y; Hamm N; Ma X; Higgs RE; Bhagwat SV; Buchanan S; Peng SB; Staschke KA; Yadav V; Yue Y; Kouros-Mehr H
PLoS One; 2014; 9(5):e98293. PubMed ID: 24874471
[TBL] [Abstract][Full Text] [Related]
49. Human gastric cancer modelling using organoids.
Seidlitz T; Merker SR; Rothe A; Zakrzewski F; von Neubeck C; Grützmann K; Sommer U; Schweitzer C; Schölch S; Uhlemann H; Gaebler AM; Werner K; Krause M; Baretton GB; Welsch T; Koo BK; Aust DE; Klink B; Weitz J; Stange DE
Gut; 2019 Feb; 68(2):207-217. PubMed ID: 29703791
[TBL] [Abstract][Full Text] [Related]
50. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.
Lu J; Ding Y; Chen Y; Jiang J; Chen Y; Huang Y; Wu M; Li C; Kong M; Zhao W; Wang H; Zhang J; Li Z; Lu Y; Yu X; Jin K; Zhou D; Zhou T; Teng F; Zhang H; Zhou Z; Wang H; Teng L
Nat Commun; 2021 Jun; 12(1):3946. PubMed ID: 34168152
[TBL] [Abstract][Full Text] [Related]
51. FGFR2 gene amplification and clinicopathological features in gastric cancer.
Matsumoto K; Arao T; Hamaguchi T; Shimada Y; Kato K; Oda I; Taniguchi H; Koizumi F; Yanagihara K; Sasaki H; Nishio K; Yamada Y
Br J Cancer; 2012 Feb; 106(4):727-32. PubMed ID: 22240789
[TBL] [Abstract][Full Text] [Related]
52. PAK1 silencing is synthetic lethal with CDK4/6 inhibition in gastric cancer cells via regulating PDK1 expression.
Qian Y; Wu X; Wang H; Hou G; Han X; Song W
Hum Cell; 2020 Apr; 33(2):377-385. PubMed ID: 31919718
[TBL] [Abstract][Full Text] [Related]
53. Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib.
Novo SM; Wedge SR; Stark LA
Sci Rep; 2017 Sep; 7(1):12020. PubMed ID: 28931905
[TBL] [Abstract][Full Text] [Related]
54. Frequent gene amplification predicts poor prognosis in gastric cancer.
Shi J; Yao D; Liu W; Wang N; Lv H; He N; Shi B; Hou P; Ji M
Int J Mol Sci; 2012; 13(4):4714-4726. PubMed ID: 22606006
[TBL] [Abstract][Full Text] [Related]
55. Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer.
Wang L; Xiao Y; Ping Y; Li J; Zhao H; Li F; Hu J; Zhang H; Deng Y; Tian J; Li X
PLoS One; 2014; 9(8):e104282. PubMed ID: 25137136
[TBL] [Abstract][Full Text] [Related]
56. Genetic analysis of tumorigenesis: XXXII. Localization of constitutionally amplified KRAS sequences to Chinese hamster chromosomes X and Y by in situ hybridization.
Stenman G; Anisowicz A; Sager R
Somat Cell Mol Genet; 1988 Nov; 14(6):639-44. PubMed ID: 3057654
[TBL] [Abstract][Full Text] [Related]
57. [Standardization of evaluation for target molecule in cancer therapy].
Ochiai A
Gan To Kagaku Ryoho; 2011 May; 38(5):709-14. PubMed ID: 21566428
[TBL] [Abstract][Full Text] [Related]
58. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
59. KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers.
Doherty GJ; Kerr EM; Martins CP
Trends Mol Med; 2017 May; 23(5):377-378. PubMed ID: 28372922
[TBL] [Abstract][Full Text] [Related]
60. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
Cristescu R; Lee J; Nebozhyn M; Kim KM; Ting JC; Wong SS; Liu J; Yue YG; Wang J; Yu K; Ye XS; Do IG; Liu S; Gong L; Fu J; Jin JG; Choi MG; Sohn TS; Lee JH; Bae JM; Kim ST; Park SH; Sohn I; Jung SH; Tan P; Chen R; Hardwick J; Kang WK; Ayers M; Hongyue D; Reinhard C; Loboda A; Kim S; Aggarwal A
Nat Med; 2015 May; 21(5):449-56. PubMed ID: 25894828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
